


MOZEC SEB PTCA-1 Study

Study Highlights

- Principal Investigator: Dr. S. Selvamani
- Mozec SEB PTCA-1 is a prospective, multicenter, real-world, single-arm post-market study to evaluate safety and performance of Mozec™ Sirolimus-Eluting Percutaneous Transluminal Coronary Angioplasty balloon dilatation catheter for native coronary artery disease in daily clinical practice
- The present study ascertains favorable safety and performance of Mozec demonstrated by low cumulative MACE rate at 12-month follow-up



❖ Study Design

A Prospective, multi-center, single-arm, real-world, post-marketing study



A total of 110 patients were enrolled, out of which 79 patients have completed 6 months and 32 patients have completed 12 months follow-up



9 investigational sites across India



Clinical follow-up at 1-month
Telephonic/Clinical follow-up for 1-year and 2-year



Angiographic follow-up at 6 months

❖ Study Results




Figure 1: Baseline lesion characteristics of study population




Figure 2: Baseline disease vessels characteristics of study population

❖ References

1. CTRI number: CTRI/2017/03/008002
<http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=2017&EncHid=&userName=CTRI/2017/03/008002>
2. Selvamani S. PTCA to significantly diseased LCX: A challenge. Mozec SEB. Challenging Case TCT 2018.
3. Parikh K. PTCA of LIMA to LAD Graft Using Drug-Eluting Balloon. Mozec SEB. Challenging Case CSI-NIC 2019.
4. Chag M. PTCA of LIMA to LAD Graft Using Drug-Eluting Balloon. Mozec SEB. Challenging Case. TCT 2019.
5. Selvamani S. Short-term clinical outcomes after treatment of de novo lesions, in-stent restenosis and totally occluded stenotic lesions using sirolimus-eluting balloon. EURO PCR 2019.
6. Parikh K. Clinical outcomes after treatment of de novo lesions, in-stent restenosis and totally occluded stenotic lesions using sirolimus-eluting balloon. Accepted as E-poster EuroPCR 2020.